Amylin, with and without GLP1: Eloralinitide
We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.
As part of Eli Lilly's upcoming flurry of updates, one of their projects that is under way deserves a bigger spot light: Eloralinitide.
Eloralinitide isn't a GLP1 Receptor Agonist in it's own right – it's actually a drug meant to be taken alongside a GLP1 regimen, enhancing it's effects.
Check out our quick explainer
By the '-tide' name, we know that it's a peptide (similar to Retatrutide though Retatrutide is itself a GLP1 receptor agonist peptide).
What is Eloralinitide?
Eloralinitide is an analog to the naturally produced Amylin hormone:
Contributors to Wikimedia projects
To briefly summarize the key properties of Amylin:
- It's secreted at the same time as insulin
- Impacts the pancreas
- It helps control blood sugar
- It slows gastric emptying
- Increases fullness after meals
Amylin is actually another powerful force in the reduction of appetite after eating in the human body.
Amylin helps patients with both obesity and type 2 diabetes, so it's similar to a GLP1 receptor agonist in that way.
Where is research on Eloralinitide?
Research involving humans on Eloralinitide is already ongoing, and Eli Lilly has shared some results ahead of their big summer update.
This has also reported on by sites like Fierce BioTech and BioSpace:
- 100 people received varied doses of Eloralinitide
- Participants lost a maximum of 11.3% and a minimum of 2.6% of their body weight after 12 weeks
- Patients were overweight or obese
- There was a 0.2% weight gain for people on the placebo
Eli Lilly is due to announce a full update on Eloralinitide very soon:
GLP1.Guide Staff
Eli Lilly is also recruiting for a clinical human trial:
Eli Lilly is studying Eloralinitide by itself and in combination with Tirzepatide as a boosting agent.
What are the unique benefits?
Eloralinitide works a bit differently from other GLP1s in that it helps people feel fuller longer after eating. This means that it could promote more gradual weight loss and possibly conserve lean muscle.
Eloralinitide also compares favorably to the competition, as BioSpace reported:
Metsera, meanwhile, offered Phase I results earlier this month for the ultra-long-acting amylin injectable MET-233i that showed weight loss of 8.4% at 36 days.
So we know that Eloralinitide can produce (by itself) more weight loss in a third of the time than Metsera, which is pretty impressive.
Both Novo Nordisk and Roche have started investigating and research Amylin-based "boosters" and weight loss drugs – so this trend is far from over.
We're looking forward to more data being published on the 22nd, and a new wave of even more effective GLP1s.
